Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2017, Vol. 37 Issue (3): 51-57    DOI: 10.13523/j.cb.20170307
    
Development and Application of A Double Monoclonal Antibody Sandwich ELISA for the Assay of Nodal
WU Meng-ling, ZHOU Jia-wang, DU Jun
Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
Download: HTML   PDF(878KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Background:Nodal is a member of the transforming growth factor beta (TGF-beta) super family, essential in maintaining the pluripotency of human embryonic stem cells (hESCs), which is not active in most adult tissues, its reexpression and signaling have been linked to multiple types of human cancer. Recent findings have revealed that Nodal is a critical regulator of melanoma growth, plasticity and tumorigenicity, and holds promise as a new tumor biomarker. Similar observations have been reported in multiple human cancers. To utilize Nodal as a useful biomarker for cancer detection, a double monoclonal antibody sandwich enzyme-linked immunosorbent assay (ELISA) may be a reliable, easy and cheap means. Methodology/principal findings:Recombinant Nodal was used as antigen to immunize BALB/c mice, by cell fusion between plasma cells and SP2/0 cells, 7 specific positive monoclonal antibodies were picked out, which were verified through indirect ELISA, Western blot and flow cytometry analyses. Therefore 15 pairs of antibodies can be used to set up a double monoclonal antibody sandwich ELISA, AF12-DG5 was the most appropriate antibody pairs. Combined with biotin-avidin systerm, DG5-biotin was used as detection antibody while the complex of streptavidin and HRP-biotin (mass ratio 4:1) as detection reagent. The best working concentration of antibodies were AF12 2μg/ml and DG5-biotin 2μg/ml. Linear range of this ELISA is 0~3 000pg/ml, regression equation is y=0.000 3x+0.150 5,R2=0.999, low limit of detection is 68pg/ml, average recovery is 99.6%. The result of serum detection indicates that more Nodal was expressed in 70% of gallbladder carcinoma patients, 92% of nasopharyngeal carcinoma patients and 97% of colorectal carcinoma patients, which were statistically significantly increased compare to normal human.Conclusions/significance:A sensitive and specific Nodal ELISA test has been developed. This test is high sensitive and easy to use and can discriminate cancer patients from normal person specifically. The achieved data suggest that the developed ELISA may be applicable as a research tool for detection of human cancer.



Key wordsDouble antibody sandwich ELISA      Biotin-avidin      Cell fusion techniques      Nodal      Monoclonal antibody     
Received: 26 December 2016      Published: 25 March 2017
ZTFLH:  Q816  
Cite this article:

WU Meng-ling, ZHOU Jia-wang, DU Jun. Development and Application of A Double Monoclonal Antibody Sandwich ELISA for the Assay of Nodal. China Biotechnology, 2017, 37(3): 51-57.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170307     OR     https://manu60.magtech.com.cn/biotech/Y2017/V37/I3/51

[1] Conleyba T S. Prognostic and predictive markers in cancer. DIS Markers, 2004, 20(2):35-43.
[2] Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clinical Chemistry, 2002, 48(8):1151-1159.
[3] 杨立新,郁卫东,刘桂生,等.Nodal信号的研究进展.中国生物工程杂志,2003,23(3):15-19. Yang L X, Yu W D, Liu G S, et al. Recent advances in nodal signaling. China Biotechnology, 2003,23(3):15-19.
[4] Seo H J, Kim Y J, Cho K B, et al. Nodal metastasis after successful endoscopic submucosal dissection for colorectal mucosal cancer. Endoscopy, 2011, 43(Suppl 2 UCTN):E374-E375.
[5] Quail D F, Walsh L A, Zhang Gui-hua, et al. Embryonic protein nodal promotes breast cancer vascularization. Cancer Research, 2012, 72(15):3851-3863.
[6] 方瑞,杜军.Nodal信号调控与肿瘤的研究现状.中华肿瘤防治杂志,2012,19(11):872-876. Fang R, Du J. Research advances of regulation of Nodal signal and tumor. Chinese Journal of Cancer Prevention and Treatment, 2012,19(11):872-876.
[7] Strizzi L, Hardy K M, Kirschmann D A, et al. Nodal expression and detection in cancer:experience and challenges. Cancer Research, 2012, 72(8):1915-1920.
[8] Engvall E, Karin J, Perlmann P. Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes. Biochimica ET Biophysica ACTA (Bba)-Protein STRU, 1971, 251(3):427-434.
[9] Zangar R C, Daly D S, White A M. ELISA microarray technology as a high-throughput system for cancer biomarker validation. Expert Review of Proteomics, 2006, 3(1):37-44.
[10] Gan S D, Patel K R. Enzyme immunoassay and enzyme-linked immunosorbent assay. Journal of Investigative Dermatology, 2013, 133(9):1-3.
[11] 李玲玲,江冠民,张革,等.人源Nodal成熟肽的原核表达及多克隆抗体的制备.细胞与分子免疫学杂志,2011,27(8):880-882,88. Li L L, Jiang G M, Zhang G, et al. Prokaryotic expression and polyclonal antibody preparation of human Nodal mature peptide. Journal of Cellular and Molecular Immunology, 2011,27(8):880-882,88.
[12] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡.中国肿瘤,2014,23(1):1-10. Chen M Q, Zhang S W, Zeng H M et al. Report of cancer incidence and mortality in China,2010. Bulletin of Chinese Cancer, 2014,23(1):1-10.
[13] Lech G, Ssotw n' ski R, Sodkowski M, et al. Colorectal cancer tumour markers and biomarkers:recent therapeutic advances. World Journal of Gastroenterology, 2016,22(5):1745-1755.
[14] Goulart B L, Clark J W, Pien H H, et al. Trends in the use and role of biomarkers in phase I oncology trials. Clinical Cancer Research, 2007, 13(22):6719-6726.
[15] Hsu S M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques a comparison between ABC and unlabeled antibody (PAP) procedures. The Journal of Histochemistry and Cytochemistry, 1981, 29(4):577-580.
[16] Grumbach I M, Veh R W. The SA rABC technique a new ABC procedure for detection of antigens at increased sensitivity. The Journal of Histochemistry and Cytochemistry, 1995, 43(1):31-37.

[1] ZHAO Yan-shu,ZHANG Jin-hua,SONG Hao. Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast[J]. China Biotechnology, 2020, 40(8): 74-83.
[2] WANG Meng,SONG Hui-ru,CHENG Yu-jie,WANG Yi,YANG Bo,HU Zheng. Accurate Detection of Streptococcus pneumoniae by Using Ribosomal Protein L7 / L12 as Molecular Marker[J]. China Biotechnology, 2020, 40(4): 34-41.
[3] JIANG Yi-fan,JIA Yu,Wang Long,WANG Zhi-ming. The Glycosylation Design and Control of Monoclonal Antibody by Cell Culture[J]. China Biotechnology, 2019, 39(8): 95-103.
[4] LIU Guo-fang,LIU Xiao-zhi,GAO Jian,WANG Zhi-ming. Effects of Host Cell Residual Proteins on the Quality and Their Quality Control of Monoclonal Antibody[J]. China Biotechnology, 2019, 39(10): 105-110.
[5] Jian-wei REN,Jun LI,Shang-ze LI. Human CT55 Protein Prokaryotic Expression and Its Production of Monoclonal Antibody[J]. China Biotechnology, 2018, 38(11): 1-8.
[6] Kai-yun MAO,Yue-lei FAN,Heng-zhe WANG,Da-ming CHEN. Market Competition Pattern of Global PD-1/PD-L1 Monoclonal Antibody[J]. China Biotechnology, 2018, 38(11): 103-115.
[7] Jing-jing SUN,Wei-wei ZHOU,Lei-ming ZHOU,Qiao-hui ZHAO,Gui-lin LI. Advance in Large-Scale Culture of Hybridoma Cells in Vitro[J]. China Biotechnology, 2018, 38(10): 82-89.
[8] WANG Yun-long, ZHAO Er-xia, LI Yu-lin. Expression, Purification and Identification of Thymidine Kinase 1 Recombinant Protein[J]. China Biotechnology, 2017, 37(9): 15-22.
[9] LI Min, WU Ri-wei. The Market Overview of Monoclonal Antibodies in Both Domestic and Abroad[J]. China Biotechnology, 2017, 37(3): 106-114.
[10] REN Hua-jing, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian. Progression of Central Nervous System Disease Therapeutic Antibody Drug Application[J]. China Biotechnology, 2016, 36(9): 54-58.
[11] GONG Long-cai, LUO Zhen-ming, YANG Yan-qing, WANG Zhen-yu, XIANG Jun-jian, WANG Hong. Prokaryotic Expression and Identification of cTnI-linker-TnC Fusion Protein[J]. China Biotechnology, 2015, 35(4): 48-53.
[12] ZHANG Yin-chuan, LIU Meng-meng, ZHANG Ya-ting, GUI Fang, ZHANG Ai-hua, BI Lan, PAN Yong-bin. Construction and Screening of Recombinant Cell Line Expressing Fully-human mAbs against Human IgE[J]. China Biotechnology, 2015, 35(3): 66-74.
[13] WANG Lan, XIA Mao, GAO Kai. The Development and Quality Control of Antibody-Drug Conjugates[J]. China Biotechnology, 2014, 34(4): 85-94.
[14] QUAN Mei-yu, GUO Qiang, ZHANG Kun-shui, FANF Rui, LI Cui-lin, DU Jun. Generation of Two Mouse Melanoma Cell Lines Stable Overexpression or Silencing of Nodal and Identification of EMT Phenotype[J]. China Biotechnology, 2014, 34(3): 1-8.
[15] GAO Kai, XU Zhi-kai, REN Yue-ming, WAN Lan, WANG Jun-zhi, GUO Zhong-ping. Points to Consider for the General Monograph of Monoclonal Antibody Based Biotherapeutics in Chinese Pharamacopeia[J]. China Biotechnology, 2014, 34(1): 127-134.